Hamlet BioPharma - the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, has secured continued production of Alpha1-peptide with the Swiss public company
Hamlet BioPharma announces an important milestone by advancing pharmaceutical manufacturing of the Alpha1 peptide with the
The Alpha1H complex, which is produced from the synthetic alpha1 peptide, has shown excellent clinical efficacy and stability.
"Securing Alpha1 peptide production on a large scale is essential at this stage to meet the anticipated demand for Alpha1H as our clinical program for bladder cancer is advancing towards Phase III.", says
For more information, please contact
Catharina Svanborg, Chairman of the Board,
catharina.svanborg@hamletpharma.com
martin.erixon@hamletpharma.com
https://news.cision.com/hamlet-biopharma-ab--publ-/r/hamlet-biopharma-secures-large-scale-alpha1-peptide-production-in-an-agreement-with-polypeptide-grou,c3963540
https://mb.cision.com/Main/13052/3963540/2741365.pdf
(c) 2024 Cision. All rights reserved., source